Synairgen PLC's Richard Marsden (LON:SNG) talks to Proactive London's Katie Pilbeam about the £80m share placing to finance its lead drug through final-stage clinical trials in patients with severe coronavirus (COVID-19).
Marsden explains the reason behind involving 900 patients in 20 countries for the phase III clinical trial which is set to get away in November. He says he wants to 'complete the trial as quickly as possible' and the 'eventual data set will have lots of different ethnicities and a different standard of care in the background'.
Synairgen has teamed up with Parexel to enable such a large amount of research to be conducted and 'enable rapid approvals around the world'.
Marsden says if all goes to plan 'we would have finished a phase II and III programme all in one year', which is 'very unusual'.
